Trials / Completed

CompletedNCT06613763

A Study of RAY1225 in Participants With Impaired Kidney Function

Pharmacokinetics of RAY1225 Following Administration to Subjects With Impaired Renal Function

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 32 (actual)

Sponsor: Guangdong Raynovent Biotech Co., Ltd · Industry
Sex: All
Age: 18 Years – 75 Years
Healthy volunteers: Accepted

Summary

The purpose of this study is to assess how fast RAY1225 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

Conditions

Kidney Impairment

Interventions

Type	Name	Description
DRUG	RAY1225	Administered SC

Timeline

Start date: 2024-09-11
Primary completion: 2025-01-10
Completion: 2025-01-20
First posted: 2024-09-26
Last updated: 2025-03-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06613763. Inclusion in this directory is not an endorsement.